Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

about

The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.

P2860

Q38841082-141010A1-5D8F-47A1-AFD7-53BB008DDD4B Q47953839-7C2A5872-E80A-4B81-85E2-F0599F3F6337

P2860

Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

Item

http://www.wikidata.org/entity/Q38541877

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Metastatic castration-resistan ...... rone acetate and enzalutamide.

@en

type

Item

label

Metastatic castration-resistan ...... rone acetate and enzalutamide.

@en

prefLabel

Metastatic castration-resistan ...... rone acetate and enzalutamide.

@en

P1476

Metastatic castration-resistan ...... erone acetate and enzalutamide

@en

P2093

Alessandra Modena

http://www.w3.org/2001/XMLSchema#string

Chiara Ciccarese

http://www.w3.org/2001/XMLSchema#string

Davide Bimbatti

http://www.w3.org/2001/XMLSchema#string

Emanuela Fantinel

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Abiraterone in metastatic prostate cancer without previous chemotherapy

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Overcoming mutation-based resistance to antiandrogens with rational drug design

Lineage dependency and lineage-survival oncogenes in human cancer

P304

1037-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2015.1063423

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giampaolo Tortora

F Massari

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26134919

http://www.w3.org/2001/XMLSchema#string

Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

about

P2860

P2860

Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698